Gastrointestinal (GI): NSAIDs that block COX-one action have correlations with GI problems mainly because of the inhibition from the synthesis of gastroprotective brokers for example PGE2 along with other prostaglandins. This inhibition causes diminished mucin manufacturing by gastric epithelial cells, less bicarbonate secretion, and fewer epitheli